Posts Tagged ‘pfizer’

With the fourth quarter earnings season now complete, we take a look at the fourth quarter earnings performances of the Dow stocks.

Pfizer has consistently underperformed the broader market indexes over the last several years, but finally looks poised to change that trend.

While declining sales & earnings are likely to capture the headlines, we expect Pfizer to post second quarter results that are slightly ahead of Wall Street’s estimates.

We believe that the cost cutting measures that Pfizer has undertaken could produce better than expected first quarter earnings.